PT  - JOURNAL ARTICLE
AU  - Ilse Krebs
AU  - Leopold Schmetterer
AU  - Agnes Boltz
AU  - Reinhard Told
AU  - Veronika Vécsei-Marlovits
AU  - Stefan Egger
AU  - Ulrich Schönherr
AU  - Anton Haas
AU  - Siamak Ansari-Shahrezaei
AU  - Susanne Binder
AU  - for the MANTA Research Group
TI  - A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
AID  - 10.1136/bjophthalmol-2012-302391
DP  - 2013 Mar 01
TA  - British Journal of Ophthalmology
PG  - 266--271
VI  - 97
IP  - 3
4099  - http://bjo.bmj.com/content/97/3/266.short
4100  - http://bjo.bmj.com/content/97/3/266.full
SO  - Br J Ophthalmol2013 Mar 01; 97
AB  - Aim The current accepted standard treatment for neovascular age-related macular degeneration (AMD) consists of antivascular endothelial growth factor agents including ranibizumab and bevacizumab. The aim of the study was to examine whether bevacizumab is inferior to ranibizumab with respect to maintaining/improving visual acuity. Methods In this prospective randomised parallel group multicentre trial patients aged more than 50 years with treatment naive nAMD were included at 10 Austrian centres. Patients were randomised to treatment either with 0.5 mg ranibizumab or 1.25 mg bevacizumab. Both groups received three initial monthly injections and thereafter monthly evaluation of visual acuity and the activity of the lesion. Re-treatment was scheduled as needed. Outcome measures were early treatment of diabetic retinopathy visual acuity, retinal thickness, lesion size and safety evaluation. Results A total of 321 patients were recruited of which four had to be excluded due to different reasons. Of the 317 remaining patients 154 were randomised into the bevacizumab group and 163 into the ranibizumab group. At month 12, there was a mean increase of early treatment of diabetic retinopathy visual acuity of 4.9 letters in the bevacizumab and 4.1 letters in the ranibizumab group (p=0.78). Furthermore, there were no significant differences in the decrease of retinal thickness, change of lesion size and number of adverse events between the groups. Conclusions Bevacizumab was equivalent to ranibizumab for visual acuity at all time points over 1 year. There was no significant difference of decrease of retinal thickness or number of adverse events.